Literature DB >> 29655447

Ocular Myasthenia.

Mohammed Al-Haidar1, Michael Benatar1, Henry J Kaminski2.   

Abstract

Ocular myasthenia is a form of myasthenia gravis in which weakness is restricted to the ocular muscles and may produce significant visual disability. Patients present with fluctuating ptosis, diplopia, or a combination of both. Examination may show any type of ocular motility deficit ranging from isolated muscle palsy to complete ophthalmoplegia. Cogan lid twitch, enhanced ptosis, peek sign, and saccadic fatigue are specific examination findings that support the clinical diagnosis of myasthenia gravis. Confirmation of the diagnosis is challenging with autoantibody serology, and repetitive nerve stimulation studies are often negative.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylcholine receptor; Double vision; Extraocular muscle; Myasthenia gravis; Ocular myasthenia; Prednisone; Ptosis

Mesh:

Year:  2018        PMID: 29655447     DOI: 10.1016/j.ncl.2018.01.003

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  12 in total

Review 1.  Adalimumab-induced myasthenia gravis: case-based review.

Authors:  Eleftherios Pelechas; Tereza Memi; Theodora E Markatseli; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Rheumatol Int       Date:  2020-04-22       Impact factor: 2.631

Review 2.  [Myasthenia gravis].

Authors:  Wolfgang Müllges; Guido Stoll
Journal:  Nervenarzt       Date:  2019-10       Impact factor: 1.214

3.  Prediction of the generalization of myasthenia gravis with purely ocular symptoms at onset: a multivariable model development and validation.

Authors:  Feng Li; Hongbin Zhang; Ya Tao; Frauke Stascheit; Jiaojiao Han; Feng Gao; Hongbo Liu; Alberto Carmona-Bayonas; Zhongmin Li; Jens-C Rueckert; Andreas Meisel; Song Zhao
Journal:  Ther Adv Neurol Disord       Date:  2022-06-21       Impact factor: 6.430

4.  An Outperforming Artificial Intelligence Model to Identify Referable Blepharoptosis for General Practitioners.

Authors:  Ju-Yi Hung; Ke-Wei Chen; Chandrashan Perera; Hsu-Kuang Chiu; Cherng-Ru Hsu; David Myung; An-Chun Luo; Chiou-Shann Fuh; Shu-Lang Liao; Andrea Lora Kossler
Journal:  J Pers Med       Date:  2022-02-15

5.  Ophthalmologic manifestations in myasthenia gravis: presentation and prognosis.

Authors:  Onur Akan; Leyla Baysal-Kirac
Journal:  Acta Neurol Belg       Date:  2021-01-04       Impact factor: 2.396

Review 6.  A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature.

Authors:  Maria Elena Farrugia; John A Goodfellow
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

7.  Prognostic predictors of remission in ocular myasthenia after thymectomy.

Authors:  Xiang Liu; Wangyan Zhou; Jun Hu; Mingsong Hu; Wenkui Gao; Shan Zhang; Wei Zeng
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

8.  Myasthenia gravis: MuSK MG, late-onset MG and ocular MG.

Authors:  Feza Deymeer
Journal:  Acta Myol       Date:  2020-12-01

9.  Cerebrospinal fluid hypovolemia syndrome mimicking ocular myasthenia gravis: A case report.

Authors:  Akihiro Shinkai; Yasuhiro Shinmei; Akihiro Takahashi; Kayoko Nakamura; Yoshiaki Tagawa; Shinki Chin; Susumu Ishida
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-15

Review 10.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.